Core Viewpoint - The stock of Lai Kai Pharmaceutical-B (02105) rose over 5% following the announcement of an exclusive agreement with Qilu Pharmaceutical for the research, development, and commercialization of LAE002 in China [1] Group 1: Company Developments - Lai Kai Pharmaceutical's stock increased by 5.63%, reaching HKD 16.9, with a trading volume of HKD 28.6972 million [1] - The company has signed an exclusive agreement with Qilu Pharmaceutical, allowing Qilu to conduct research and commercialization of LAE002 in China [1] - Lai Kai is responsible for completing the Phase III clinical trial for HR+/HER2- breast cancer until the first indication receives new drug application approval in China [1] Group 2: Financial Aspects - The agreement includes a non-refundable upfront payment of up to RMB 530 million and milestone payments related to clinical development [1] - The total potential upfront and milestone payments could reach RMB 2.045 billion, along with a sales revenue share of 10% to 20% from future net sales in the licensed region [1] Group 3: Pipeline Progress - According to Yongxing Securities, LAE002 is expected to submit its New Drug Application (NDA) in the first half of 2026 [1] - The company's pipeline is progressing well, with promising data for LAE102 and FDA approval for the IND application of LAE103 [1] - Yongxing Securities has initiated coverage of LAE102 using the DCF valuation method and has given the company a "buy" rating [1]
港股异动 来凯医药-B(02105)早盘涨超5% LAE002预计26年上半年提交NDA